ArticleInvestigative and clinical urology2025
Revisiting angiomyolipomas: The significance of a rich blood supply on imaging for risk-adapted decision making.
Article in Investigative and clinical urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeActive surveillance is the preferred management for most renal angiomyolipomas (AMLs) but no risk-adapted follow-up strategy has been established. We aimed to assess the dynamics associated with hemorrhagic complications (HC) and tumor growth (TG) at long-term follow-up of AMLs. MATERIALS AND
methodsA single-center retrospective study was conducted, enrolling patients with an AML diagnosed by computed tomography or magnetic resonance imaging. Kaplan-Meier analyses were performed to estimate HC risk and multivariate logistic regression analyses were carried out to evaluate predictors of TG and HC.
resultsA total of 150 patients were included. The median follow-up was 64.5 months (interquartile range [IQR] 25-102). Median tumor size at diagnosis was 14 mm (IQR 8-26). During follow-up, 12 patients (8.0%) required selective angioembolization, including 6 in whom the procedure was urgent due to spontaneous bleeding. At 5 years of follow-up, we found a 4.5% risk of HC and 3.6% of patients had a clinically significant growth rate of ≥3 mm/year. The existence of a rich blood supply (odds ratio [OR] 11.10, 95% confidence interval [CI] 1.68-23.54), and the size of AMLs at diagnosis (OR 1.02, 95% CI 1.01-1.04) were predictors for HC.
conclusionsRenal AMLs have a minimal size progression and a very low risk of HC, allowing use of active surveillance as a first-line approach. Imaging features, such as the existence of a rich blood supply, could be useful in identifying patients at higher risk of bleeding for the purpose of risk-adapted decision making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.